Reprogramming CAR T-Cells with designed bioPROTACs.

Area of Science:

• Immunology
• Molecular Biology
• Biotechnology

Background:

• Gene editing enhances CAR T-cell function by disrupting negative regulators.
• Existing gene editing methods have limitations for therapeutic applications.

Purpose of the Study:

• To explore de novo-designed targeted degraders (bioPROTACs) as an alternative to gene editing for CAR T-cell enhancement.
• To investigate the efficacy of bioPROTACs in targeting DNMT3A, a regulator of T-cell exhaustion.

Main Methods:

• Designed and generated bioPROTACs for CAR T-cell applications.
• Expressed bioPROTACs in CAR T-cells targeting DNMT3A.
• Evaluated the functional effects of bioPROTAC expression on T-cell phenotype.

Main Results:

• BioPROTAC expression in CAR T-cells targeting DNMT3A phenocopied gene knockout effects.
• The bioPROTAC approach demonstrated a reversible and tunable strategy.
• This method successfully reprogrammed T-cell fate, addressing T-cell exhaustion.

Conclusions:

• De novo-designed bioPROTACs provide a viable, non-gene editing alternative for enhancing CAR T-cell function.
• This reversible approach offers tunable control over T-cell fate reprogramming.
• BioPROTACs hold broad applicability for developing next-generation cell therapies.